header("Access-Control-Allow-Origin: *"); ?>
Targeting immune checkpoints, such as Programmed cell Death 1 (PD1), has improved survival in cancer patients by unleashing exhausted CD8+ T-cell […]
The present invention relates to a treatment of Th cell-associated disorders. Here, theinventors The inventors show that Treg-dependent suppressive […]
The present invention relates to a method of treating acute lymphoblastic leukemia in a patient in need thereof comprising administering to the […]
The present invention relates to an antibody, which is capable of binding to theNeuromedin N long fragment, and Neurotensin long fragment with high […]
The present invention relates to field of treatment of rheumatoid arthritis. The inventors propose that PAD4, one of the enzymes which convert […]
The present invention relates to regulatory T cell and uses thereof. By their immunosuppressive and anti-inflammatory activities, regulatory T cells […]
The present study of the regulatory T phenotype of Sézary cells led to the discovery of the expression of GARP (LRRC32) by Sézary cells. GARP has […]
T-cell lymphomas are a heterogeneous group of malignancies involving T lymphocytes and generally characterized by a poor prognosis. Among them, […]
T-cell malignancies are a broad, heterogenous group of diseases and include T-cell lymphomas and T-cell leukemias. T-cell lymphomas are a […]
There is an interest to develop anti-ROBO4 antibodies that can be suitable for the treatment of cancer. The inventors produced new human antibodies […]